Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome

被引:12
作者
Katz, Lior H.
Mor, Eitan
Brown, Marius
Bar-Nathan, Nathan
Shaharabani, Ezra
Sulkes, Jaqueline
Pappo, Orit
Tur-Kaspa, Ran
Ben-Ari, Ziv
机构
[1] Rabin Med Ctr, Liver Inst, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Dept Med D, IL-49100 Petah Tiqwa, Israel
[3] Rabin Med Ctr, Dept Organ Transplantat, IL-49100 Petah Tiqwa, Israel
[4] Rabin Med Ctr, Epidemiol Unit, IL-49100 Petah Tiqwa, Israel
[5] Rabin Med Ctr, Dept Histopathol, IL-49100 Petah Tiqwa, Israel
[6] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
biliary complications; hepatitis C virus; liver transplantation; recurrent;
D O I
10.1111/j.1399-0012.2006.00507.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Recurrent hepatitis C virus (HCV) infection is particularly aggressive in the post-liver transplantation setting, with rapid progression of liver fibrosis. Biliary complications remain a significant cause of morbidity following liver transplantation. Post-cholecystectomy biliary strictures are associated with advanced hepatic fibrosis. The aim of this retrospective study was to determine whether the presence of biliary complications affects survival in liver transplant recipients with recurrent HCV disease. The files of liver transplant recipients (53.7% male; mean age 52.7 +/- 10.3 yr) were reviewed for incidence, type and treatment of biliary complications, and findings were compared between those who developed recurrent HCV disease (n = 47, 83.9%) and those who did not (n = 9). Twenty-one biliary complications developed in 12 patients with recurrent HCV (25.5%). Treatment with endoscopic retrograde cholangiopancreatography or percutaneous transhepatic cholangiography with balloon dilatation and stent placement or surgical revision was successful in nine (75%). Three biliary complications developed in three patients with no recurrence (p = NS). There was no statistically significant association between recurrent HCV disease and biliary complications. However, among those with recurrent disease, the recurrence was severe in nine of 12 recipients with biliary complications (75%) but in only nine of 35 without biliary complications (26%) (p = 0.001). Death was documented in eight patients with severe recurrence (44.4%), including three (37.5%) with biliary complications and two (7%) with non-severe recurrence, neither of whom had biliary complications (p = 0.003). Antiviral treatment was successful in nine of 25 patients (36%) who received it. On multivariate analysis, biliary complications were a significant predictor of severe recurrence (OR 27.0, 95% confidence interval 2.07-351.4) (p = 0.012). Fibrosis stage in the second biopsy was significantly correlated with serum alanine aminotransferase (p = 0.01) and with duration of biliary obstruction (p = 0.07). In conclusion, biliary complications of liver transplantation strongly affect outcome in patients with recurrent HCV disease despite attempts to relieve the biliary obstruction and to treat the recurrent HCV disease.
引用
收藏
页码:465 / 470
页数:6
相关论文
共 21 条
[1]  
ABDELAZIZ G, 1990, AM J PATHOL, V137, P1333
[2]  
ARONSON DC, 1988, LIVER, V8, P116
[3]   Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation [J].
Berenguer, M ;
Prieto, M ;
Rayón, JM ;
Mora, J ;
Pastor, M ;
Ortiz, V ;
Carrasco, D ;
San Juan, F ;
Burgueño, MDJ ;
Mir, J ;
Berenguer, J .
HEPATOLOGY, 2000, 32 (04) :852-858
[4]   HCV-related fibrosis progression following liver transplantation:: increase in recent years [J].
Berenguer, M ;
Ferrell, L ;
Watson, J ;
Prieto, M ;
Kim, M ;
Rayón, M ;
Córdoba, J ;
Herola, A ;
Ascher, N ;
Mir, J ;
Berenguer, J ;
Wright, TL .
JOURNAL OF HEPATOLOGY, 2000, 32 (04) :673-684
[5]   Long-term outcome of hepatitis C infection after liver transplantation [J].
Cane, EJ ;
Portmann, BC ;
Naoumov, NV ;
Smith, HM ;
Underhill, JA ;
Donaldson, PT ;
Maertens, G ;
Williams, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (13) :815-820
[6]   Impact of immunosuppressive therapy on recurrence of hepatitis C [J].
Everson, GT .
LIVER TRANSPLANTATION, 2002, 8 (10) :S19-S27
[7]   Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients [J].
Fattovich, G ;
Giustina, G ;
Degos, F ;
Tremolada, F ;
Diodati, G ;
Almasio, P ;
Nevens, F ;
Solinas, A ;
Mura, D ;
Brouwer, JT ;
Thomas, H ;
Njapoum, C ;
Casarin, C ;
Bonetti, P ;
Fuschi, P ;
Basho, J ;
Tocco, A ;
Bhalla, A ;
Galassini, R ;
Noventa, F ;
Schalm, SW ;
Realdi, G .
GASTROENTEROLOGY, 1997, 112 (02) :463-472
[8]  
FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1002/hep.1840200506
[9]   Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors [J].
Gaglio, PJ ;
Malireddy, S ;
Levitt, BS ;
Lapointe-Rudow, D ;
Lefkowitch, J ;
Kinkhabwala, M ;
Russo, MW ;
Emond, JC ;
Brown, RS .
LIVER TRANSPLANTATION, 2003, 9 (10) :1028-1035
[10]   The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States [J].
Hu, KQ ;
Tong, MJ .
HEPATOLOGY, 1999, 29 (04) :1311-1316